Roger Perlmutter’s new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
AstraZeneca makes $15B bet on China to expand manufacturing and R&D
AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that’s become a go-to place for drug R&D


